| Date | Title | Description |
| 08.08.2024 | Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website | Financial release accessible online
BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor R... |
| 30.07.2024 | Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire | BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and th... |
| 18.06.2024 | Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device | BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VAS... |
| 23.05.2024 | Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes | BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "... |
| 01.04.2024 | Haemonetics Corporation Completes Acquisition of Attune Medical | BOSTON, April 1, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acqui... |
| 10.10.2023 | OpSens, Inc Acquired by Haemonetics for $345 Million | Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused comp... |
| 06.01.2023 | Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023 | BOSTON, Jan. 6, 2023 /PRNewswire/ -- Haemonetics Corporation HAE announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, February 7, 2023. The Company will hold a conference c... |
| 09.11.2021 | Haemonetics Announces CFO William P. Burke's Retirement for June 2022 | BOSTON, Nov. 9, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that William P. Burke, Execut... |
| 30.09.2021 | Haemonetics : Announces VASCADE MVP® Venous Vascular Closure System Gains the First and Only FDA Approval for Same-Day Discharge Following Atrial Fibrillation Ablation | BOSTON, Sept. 30, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that the VASCADE MVP® Venous Vasc... |
| 29.04.2021 | HAEMONETICS CORPORATION
Haemonetics : Peer-Reviewed Results of Haemonetics' Improving Plasma Collection (IMPACT) Trial Published in the Journal TRANSFUSION | BOSTON, April 29, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that the full peer-reviewed resul... |
| 29.04.2021 | Peer-Reviewed Results of Haemonetics' Improving Plasma Collection (IMPACT) Trial Published in the Journal TRANSFUSION | |
| 01.03.2021 | Haemonetics Announces Proposed Convertible Senior Notes Offering | |
| 20.01.2021 | Haemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio | |
| 02.10.2020 | Haemonetics Receives FDA Clearance For NexSys PCS® With Persona™ Technology | |
| 20.02.2015 | Telemedicine business tests Google Glass with first responders and ERs for acute care | Four hospitals are piloting Third Eye Health’s platform, including University of Texas Health Science Center. It is doing a 200 patient study to evaluate its technology through a mobile stroke ambulance. Herbstman said it expects to have da... |
| 05.05.2014 | Haemonetics closes Scotland plant, launches $100M buyback after dim quarter | Massachusetts-based Haemonetics (NYSE:HAE) is making some big moves after posting a tough 4th quarter and projecting a dim outlook for the fiscal year ahead.
The blood collection devices maker plans to close a Scotland manufacturing plant a... |
| 03.08.2012 | Haemonetics closes $550M Pall blood biz buyout | Wall Street Beat | Haemonetics (NYSE:HAE) said it closed its $550 million buyout of Pall Corp. (NYSE:PLL) and announced sharply reduced profits due to what it termed "acquisition and transformation costs."
Excluding 1-time items, earnings per share ... |
| 30.04.2012 | Haemonetics hopes to stanch red ink with $578M blood management deals | The acquisition will boost Haemonetics effort to enter the whole blood collection market.
While the Hemerus acquisition is small, Haemonetics is shelling out a whopping $551 million to acquire the blood collection, filtration and processing... |
| 22.08.2011 | Blood analysis medical device gets FDA clearance for Tem Systems | Tem Systems President Ken West said that ROTEM will supplement rather than replace existing lab tests. It will be used in circumstances when clinicians need speedy analysis of the blood.
“The real value is for trauma cases and open-heart ca... |
| 02.08.2010 | Change is in the air at Haemonetics as Nutter steps away | Brad Nutter, the turnaround artist who helped pump new life into Haemonetics Corp. (NYSE:HAE) as CEO and later chairman of the board, said he will retire from the company’s board of directors effective November 1, 2010.
The move, announced ... |
| 02.08.2010 | Nutter to leave Haemonetics in November | Nutter, 58, first came to the Braintree, Mass.-based blood management business in April 2003 after a brief retirement from a career that included executive stints at Gambro Healthcare, Syncor International, Inc. and the American Hospital Su... |
| 07.06.2010 | UPDATE: USPTO upholds Haemonetics patent in spat with Fenwal | A federal court put the kaibosh on a lower court’s decision to award $15.7 million to Haemonetics Corp. (NYSE:HAE) in a patent spat with Fenwal Inc.
Haemonetics sued Fenwal in 2005, alleging that the then-Baxter Healthcare (NYSE:BAX) subsid... |
| 04.05.2010 | Big gains for Haemonetics in fiscal 2010 | Haemonetics Corp. (NYSE:HAE) topped expectations for its recently concluded fiscal year, turning in adjusted net income of $74 million on $645 million in revenues during the 12 months ended March 31.
The $2.85-per-share adjusted profit in f... |
| 06.04.2010 | Haemonetics to lay off 170 in GlobalMed integration | Haemonetics Corp. (NYSE:HAE) plans to lay off about 170 workers and close facilities in Phoenix and Chicago as it integrates its new, $61 million acquisition, GlobalMed Technologies (OTC:GLOB).
The Braintree, Mass.-based blood management fi... |
| 19.03.2010 | Haemonetics licenses Alba Bioscience blood typing reagents | Haemonetics Corp. (NYSE:HAE) inked a deal with Quotient Biodiagnostics Group subsidiary Alba Bioscience Ltd. that gives it exclusive access to Alba’s portfolio of blood-typing reagents.
The Braintree, Mass.-based blood management products m... |
| 16.02.2010 | Miromatrix and University of Minnesota ink licensing deal | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 01.02.2010 | Haemonetics drops $60 million on GlobalMed, posts Q3 gains | Haemonetics Corp. (NYSE:HAE) is expanding its reach into hospital and blood center management, announcing a definitive agreement to pay $60 million for a California-based healthcare software company.
Company executives said the deal — the c... |
| 15.12.2009 | UPDATE: Fenwal responds to Haemonetics’ second lawsuit | Haemonetics Corp. (NYSE:HAE) is suing Fenwal Inc. again, over a component of a blood collection system Fenwal was found to have infringed early this year.
The case stems from an earlier patent infringement suit Braintree, Mass.-based Haemon... |
| - | Nutter to leave Haemonetics in November | Former CEO and company chairman Brad Nutter announces retirement from the Braintree, Mass.-based blood management company after seven years.
Brad Nutter, the turnaround artist who helped pump new life into Haemonetics Corp. (NYSE:HAE) as CE... |
| - | Telemedicine business tests Google Glass with first responders and ERs for acute care | Healthbox accelerator grad Third Eye Health sees an untapped market for Google Glass in healthcare: improving acute care by speeding up the way EMTs and ER physicians communicate with each other. In an interview with MedCity News, Third Eye... |
| - | Haemonetics Announces Proposed Convertible Senior Notes Offering | BOSTON, May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior... |
| - | Haemonetics hopes to stanch red ink with $578M blood management deals | Massachusetts-based Haemonetics Corp. announced Sunday that it will buy St. Paul, Minnesota-based Hemerus Medical for up to $27 million. It will pay another $551 million to acquire certain blood filtration and processing assets of Pall Corp... |
| - | Blood analysis medical device gets FDA clearance for Tem Systems | Medical device firm Tem Systems aims to speed up blood analysis during surgeries and trauma situations.
Tem Systems has received U.S. Food and Drug Administration 510(k) clearance on new tests for its hemostasis analyzer and now the company... |
| - | Miromatrix and University of Minnesota ink licensing deal | MINNEAPOLIS, Minnesota — Let the fundraising begin!
Miromatrix Inc., a start-up trying to commercialize the regenerative tissue research of Doris Taylor, has reached an agreement to license the technology from the University of Minnesota, a... |
